ADAMTS7 and atrial fibrillation: The primary aim of our study is to follow the effect of DOAC (rivaroxaban, apixaban or dabigatran) treatment over time on ADAMTS7 promoter methylation in newly diagnosed non-valvular atrial fibrillation (AF) patients, both in pooled analysis as well as stratified in bleeding cases and controls.